首页> 外文会议>International Symposium on Current Progress in Mathematics and Sciences >Effect of Polyblend Poly(D,L-Lactic Acid) and Polycaprolactone Composition in Captopril Microcapsule on the Encapsulation Efficiency and In vitro Dissolution Test
【24h】

Effect of Polyblend Poly(D,L-Lactic Acid) and Polycaprolactone Composition in Captopril Microcapsule on the Encapsulation Efficiency and In vitro Dissolution Test

机译:聚合物聚(D,L-乳酸)和聚己内酯组合物在Capopril微胶囊上对包封效率和体外溶解试验的影响

获取原文

摘要

Captopril is one of the angiotensin-converting enzyme (ACE) class hypertension drugs that has been considerably applied to treat hypertension and congestive heart failure. Captopril has a short half-life of 1.6-1.9 hours. The short half-life of captopril makes captopril needs to be consumed repeatedly. Microencapsulation techniques can be used to cover the lack of captopril. Captopril microcapsules were made using biodegradable polymers, namely poly(D,L-lactic acid) with polycaprolactone as coating using double emulsion (w/o/w) solvent evaporation method with span 80 and tween 80 as surfactant. Microcapsules were made by varying the composition of the polymers in polyblend to study the effect on encapsulation efficiency, surface properties and in vitro dissolution test at pH 1.2 and pH 7.4. The microcapsules were all spherical and had a smooth surface as more PCL was added to the composition in polyblend. Percent yield of microcapsules obtained was about 87 % with an average size of 0.480-0.516 μm. The results of the encapsulation efficiency were 4.94-20.69 %. In the dissolution test of each polyblend composition, microcapsules could withstand the release of captopril for 55 h. The highest drug release was 75 % for the composition of PDLLA/PCL 40:60 (% w/w) was caused by degradation of the polyblend matrix. While the composition of 20:80 (% w/w) and 30:70 (% w/w) captopril was released about 43 % and 46 % through the diffusion process. These results of polyblend PDLLA/PCL as coating material may suggest the potential as a drug delivery system for captopril.
机译:卡托普利是血管紧张素转化酶(ACE)级高血压药物之一,可显着应用于治疗高血压和充血性心力衰竭。卡托普利的少年寿命为1.6-1.9小时。卡托普利的短暂半衰期使卡托普利需要反复消耗。微胶囊化技术可用于涵盖缺乏卡托普利。使用可生物降解的聚合物制成卡托普利微胶囊,即使用具有多己酮的聚(D,L-乳酸)作为涂层,其使用双乳液(W / O / W)溶剂蒸发方法作为表面活性剂。通过改变多晶体中聚合物的组成来研究微胶囊,以研究对pH 1.2和pH7.4的对封装效率,表面性质和体外溶解试验的影响。微胶囊均为球形,并且随着更多PCL加入到聚合物中的组合物中,具有光滑的表面。所得微胶囊的百分比为约87%,平均尺寸为0.480-0.516μm。封装效率的结果为4.94-20.69%。在每种聚合物组合物的溶出试验中,微胶囊可以承受卡托普利的释放55小时。对于PDLLA / PCL 40:60(%w / w)的组成,最高药物释放为75%(%w / w)是由聚合物基质的降解引起的。虽然20:80(%w / w)和30:70(%w / w)的Captopril通过扩散过程释放约43%和46%。这些聚合物PDLLA / PCL作为涂料的结果可以提示作为卡托普利的药物递送系统的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号